Research Progress on the Application of Nanomedicines in the Treatment of Acute Myeloid Leukemia

doi:10.19894/j.issn.1000-0518.240124

Chinese Journal of Applied Chemistry ›› 2024, Vol. 41 ›› Issue (9): 1259-1270.DOI: 10.19894/j.issn.1000-0518.240124

• Review • Previous Articles

Research Progress on the Application of Nanomedicines in the Treatment of Acute Myeloid Leukemia

Zhao-Yang DIAO, Li LIU, Chen-Ming LI, Huan-Li SUN()

College of Chemistry，Chemical Engineering and Materials Science，Soochow University，Suzhou 215123，China

Received:2024-04-15 Accepted:2024-08-15 Published:2024-09-01 Online:2024-10-09
Contact: Huan-Li SUN
About author:sunhuanli@suda.edu.cn
Supported by:
the National Natural Science Foundation of China(52073196);the Undergraduate Training Program for Innovation and Entrepreneurship, Soochow University(202210285037Z)

Abstract

Abstract:

Acute myeloid leukemia （AML） is the most intractable hematological malignancy mainly diagnosed in the elderly people and is associated with a high mortality rate. Chemotherapy， as its primary treatment option， suffers from drug resistance and high toxic effects， rendering most patients intolerable. Although several small molecular targeted drugs have been approved by the US Food and Drug Administration （FDA）， they usually need to be used in combination with chemotherapeutics and are perplexed with fast clearance in vivo， high dosage and serious dose-limiting toxicity. Nanomedicines， in particular actively targeted nanomedicines， have received much attention in AML treatment in recent years due to that they can improve drug delivery efficiency， overcome drug resistance， and reduce systemic toxicities. This review introduces the conventional treatment options for AML， summarizes the research progress of nanomedicines and actively targeted nanomedicines in AML treatment. Finally， the prospects and challenges of nanomedicines for clinical translation in AML treatment are outlined. This review may provide a reference for the development and further applications of nanomedicines in AML therapy.

Key words: Acute myeloid leukemia, Nanomedicines, Liposomes, Polymeric nanomedicines, Drug delivery, Tumor-targeted therapy

CLC Number:

O633

Zhao-Yang DIAO, Li LIU, Chen-Ming LI, Huan-Li SUN. Research Progress on the Application of Nanomedicines in the Treatment of Acute Myeloid Leukemia[J]. Chinese Journal of Applied Chemistry, 2024, 41(9): 1259-1270.

Figures/Tables 5

References 77

1	DINARDO C D， ERBA H P， FREEMAN S D， et al. Acute myeloid leukaemia［J］. Lancet， 2023， 401（10393）： 2073-2086.
2	SHALLIS R M， WANG R， DAVIDOFF A， et al. Epidemiology of acute myeloid leukemia： recent progress and enduring challenges［J］. Blood Rev， 2019， 36： 70-87.
3	SHORT N J， RYTTING M E， CORTES J E. Acute myeloid leukaemia［J］. Lancet， 2018， 392（10147）： 593-606.
4	TANG K， SCHUH A C， YEE K W L. 3+7 combined chemotherapy for acute myeloid leukemia： is it time to say goodbye？［J］. Curr Oncol Rep， 2021， 23（10）： 120.
5	SCHAEFER J， CASSIDY S， WEBSTER R M. The acute myeloid leukaemia market［J］. Nat Rev Drug Discov， 2020， 19（4）： 233-234.
6	BHANSALI R S， PRATZ K W， LAI C. Recent advances in targeted therapies in acute myeloid leukemia‍［J］. J Hematol Oncol， 2023， 16（1）： 29.
7	JEN E Y， KO C W， LEE J E， et al. FDA approval： gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia［J］. Clin Cancer Res， 2018， 24（14）： 3242-3246.
8	丁建勋，杨佳臻. 抗肿瘤纳米材料［J］. 应用化学， 2022， 39（5）： 855-856.
	DING J X， YANG J Z. Anti-tumor nanomaterials［J］. Chin J Appl Chem， 2022， 39（5）： 855-856.
9	陈方敏，刘小英，于海军，等. 基于环糊精的抗肿瘤药物主客体递送系统研究进展［J］. 应用化学， 2023， 40（7）： 964-975.
	CHEN F M， LIU X Y， YU H J， et al. Advancement of cyclodextrin-based host-guest drug delivery system for antitumor therapy［J］. Chin J Appl Chem， 2023， 40（7）： 964-975.
10	ALLEGRA A， DI GIOACCHINO M， TONACCI A， et al. Nanomedicine for immunotherapy targeting hematological malignancies： current approaches and perspective［J］. Nanomaterials， 2021， 11（11）： 2792.
11	JANANI G， GIRIGOSWAMI A， GIRIGOSWAMI K. Advantages of nanomedicine over the conventional treatment in Acute myeloid leukemia［J］. J Biomater Sci-Polym Ed， 2024， 35（3）： 415-441.
12	CI T Y， ZHANG W T， QIAO Y Y， et al. Delivery strategies in treatments of leukemia［J］. Chem Soc Rev， 2022， 51（6）： 2121-2144.
13	KANTARJIAN H， RAVANDI F， O'BRIEN S， et al. Intensive chemotherapy does not benefit most older patients （age 70 years or older） with acute myeloid leukemia［J］. Blood， 2010， 116（22）： 4422-4429.
14	CARTER J L， HEGE K， YANG J， et al. Targeting multiple signaling pathways： the new approach to acute myeloid leukemia therapy［J］. Signal Transduct Target Ther， 2020， 5（1）： 288.
15	ARAI Y， CHI S， MINAMI Y， et al. FLT3-targeted treatment for acute myeloid leukemia［J］. Int J Hematol， 2022， 116（3）： 351-363.
16	DAVER N， SCHLENK R F， RUSSELL N H， et al. Targeting FLT3 mutations in AML： review of current knowledge and evidence［J］. Leukemia， 2019， 33（2）： 299-312.
17	STONE R M， MANDREKAR S J， SANFORD B L， et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation［J］. N Engl J Med， 2017， 377（5）： 454-464.
18	FIGUEROA M E， ABDEL-WAHAB O， LU C， et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype， disrupt TET2 function， and impair hematopoietic differentiation［J］. Cancer Cell， 2010， 18（6）： 553-567.
19	KIM E S. Enasidenib： first global approval［J］. Drugs， 2017， 77（15）： 1705-1711.
20	DHILLON S. Ivosidenib： first global approval［J］. Drugs， 2018， 78（14）： 1509-1516.
21	SHORT N J， KONOPLEVA M， KADIA T M， et al. Advances in the treatment of acute myeloid leukemia： new drugs and new challenges［J］. Cancer Discov， 2020， 10（4）： 506-525.
22	JONAS B A， POLLYEA D A. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia［J］. Leukemia， 2019， 33（12）： 2795-2804.
23	CORTES J E， HEIDEL F H， HELLMANN A， et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome［J］. Leukemia， 2019， 33（2）： 379-389.
24	DOHNER H， WEI A H，LOWENBERG B. Towards precision medicine for AML［J］. Nat Rev Clin Oncol， 2021， 18（9）： 577-590.
25	HOY S M. Glasdegib： first global approval［J］. Drugs， 2019， 79（2）： 207-213.
26	DRAGO J Z， MODI S， CHANDARLAPATY S. Unlocking the potential of antibody-drug conjugates for cancer therapy‍［J］. Nat Rev Clin Oncol， 2021， 18（6）： 327-344.
27	FU Z W， LI S J， HAN S F， et al. Antibody drug conjugate： the “biological missile” for targeted cancer therapy‍［J］. Signal Transduct Target Ther， 2022， 7（1）： 93.
28	DUMONTET C， REICHERT J M， SENTER P D， et al. Antibody-drug conjugates come of age in oncology［J］. Nat Rev Drug Discov， 2023， 22（8）： 641-661.
29	GRIFFIN J D， LINCH D， SABBATH K， et al. A monoclonal-antibody reactive with normal and leukemic human myeloid progenitor cells［J］. Leukemia Res， 1984， 8（4）： 521-534.
30	MUÑOZ L， NOMDEDÉU J F， LÓPEZ O， et al. Interleukin-3 receptor α chain （CD123） is widely expressed in hematologic malignancies［J］. Haematologica， 2001， 86（12）： 1261-1269.
31	KUNG SUTHERLAND M S， WALTER R B， JEFFREY S C， et al. SGN-CD33A： a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML［J］. Blood， 2013， 122（8）： 1455-1463.
32	STEIN E M， WALTER R B， ERBA H P， et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia［J］. Blood， 2018， 131（4）： 387-396.
33	ERBA H P， LEVY M Y， VASU S， et al. A phase 1b study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed acute myeloid leukemia （AML）［J］. Blood， 2016， 128（22）： 211.
34	KOVTUN Y， JONES G E， ADAMS S， et al. A CD123-targeting antibody-drug conjugate， IMGN632， designed to eradicate AML while sparing normal bone marrow cells［J］. Blood Adv， 2018， 2（8）： 848-858.
35	LARGE D E， ABDELMESSIH R G， FINK E A， et al. Liposome composition in drug delivery design， synthesis， characterization， and clinical application［J］. Adv Drug Delivery Rev， 2021， 176： 113851.
36	WANG S， CHEN Y， GUO J， et al. Liposomes for tumor targeted therapy： a review［J］. Int J Mol Sci， 2023， 24（3）： 2643.
37	韩旭，丁冠宇，董青，等. 基于脂质体的纳米基因载体的研究进展［J］. 应用化学， 2018， 35（7）： 735-744.
	HAN X， DING G Y， DONG Q， et al. Research progress of nano-gene carriers based on liposomes［J］. Chin J Appl Chem， 2018， 35（7）： 735-744.
38	KRAUSS A C， GAO X， LI L， et al. FDA approval summary：（daunorubicin and cytarabine） liposome for injection for the treatment of adults with high-risk acute myeloid leukemia［J］. Clin Cancer Res， 2019， 25（9）： 2685-2690.
39	NGUYEN T M， JAMBHRUNKAR M， WONG S S， et al. Targeting acute myeloid leukemia using sphingosine kinase 1 inhibitor-loaded liposomes［J］. Mol Pharmaceut， 2023， 20（8）： 3937-3946.
40	MITCHELL M J， BILLINGSLEY M M， HALEY R M， et al. Engineering precision nanoparticles for drug delivery［J］. Nat Rev Drug Discov， 2021， 20（2）： 101-124.
41	LIANG B， JIANG D W， PAN L Q， et al. Lipase-triggered drug release from BCL2 inhibitor ABT-199-loaded nanoparticles to elevate anti-leukemic activity through enhanced drug targeting on the mitochondrial membrane［J］. Acta Biomater， 2022， 145： 246-259.
42	MEHROTRA N， ANEES M， TIWARI S， et al. Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy［J］. Nanomed-Nanotechnol Biol Med， 2022， 47： 102627.
43	XIE J， ZHAO X， ZHANG P， et al. Codelivery of BCL2 and MCL1 inhibitors enabled by phenylboronic acid-functionalized polypeptide nanovehicles for synergetic and potent therapy of acute myeloid leukemia［J］. Adv Sci， 2023， 10（8）： 2204866.
44	XU X， WANG J， TONG T， et al. A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia［J］. Haematologica， 2022， 107（10）： 2344-2355.
45	YU Y， MENG Y， XU X， et al. A ferroptosis-inducing and leukemic cell-targeting drug nanocarrier formed by redox-responsive cysteine polymer for acute myeloid leukemia therapy［J］. ACS Nano， 2023， 17（4）： 3334-3345.
46	GU W X， QU R B， MENG F H， et al. Polymeric nanomedicines targeting hematological malignancies［J］. J Control Release， 2021， 337： 571-588.
47	QIU J， CHENG R， ZHANG J， et al. Glutathione-sensitive hyaluronic acid-mercaptopurine prodrug linked via carbonyl vinyl sulfide： a robust and CD44-targeted nanomedicine for leukemia［J］. Biomacromolecules， 2017， 18（10）： 3207-3214.
48	BAE K H， LAI F， MONG J， et al. Bone marrow-targetable green tea catechin-based micellar nanocomplex for synergistic therapy of acute myeloid leukemia［J］. J Nanobiotechnol， 2022， 20（1）： 481.
49	SUN D， ZHOU J K， ZHAO L S， et al. Novel curcumin liposome modified with hyaluronan targeting CD44 plays an anti-leukemic role in acute myeloid leukemia［J］. ACS Appl Mater Interfaces， 2017， 9（20）： 16858-16869.
50	SHAO Y P， LUO W D， GUO Q Y， et al. In vitro and in vivo effect of hyaluronic acid modified， doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy‍［J］. Drug Des Dev Ther， 2019， 13： 2043-2055.
51	GU W X， LIU T H， FAN D Y， et al. A6 peptide-tagged， ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+acute myeloid leukemia［J］. J Control Release， 2021， 329： 706-716.
52	PALLARÈS V， UNZUETA U， FALGÀS A， et al. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model［J］. Biomaterials， 2022， 280： 121258.
53	PALLARÈS V， UNZUETA U， FALGÀS A， et al. An auristatin nanoconjugate targeting CXCR4⁺ leukemic cells blocks acute myeloid leukemia dissemination［J］. J Hematol Oncol， 2020， 13（1）： 36.
54	DÍAZ R， PALLARÈS V， CANO-GARRIDO O， et al. Selective CXCR4 cancer cell targeting and potent antineoplastic effect by a nanostructured version of recombinant ricin［J］. Small， 2018， 14（26）： 1800665.
55	PALLARÈS V， NÚÑEZ Y， SÁNCHEZ-GARCÍA L， et al. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4［J］. J Control Release， 2021， 335： 117-129.
56	XIA Y F， AN J N， LI J Y， et al. Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia［J］. Bioact Mater， 2023， 21： 499-510.
57	WANG C L， ZHANG W， HE Y J， et al. Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects［J］. Nat Nanotechnol， 2021， 16（12）： 1413-1423.
58	WU X Z， JIAO Z G， ZHANG J Y， et al. Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier［J］. J Nanobiotechnol， 2023， 21（1）： 126.
59	YUE S J， AN J N， ZHANG Y F， et al. Exogenous antigen upregulation empowers antibody targeted nanochemotherapy of leukemia［J］. Adv Mater， 2023， 35（32）： 2209984.
60	DU J W， YUE S J， LI C M， et al. Exogenous CD38 upregulation enables high-efficacy dually cascade targeted molecular therapy of leukemia［J］. Nano Today， 2023， 50： 101872.
61	LI H， XU S L， QUAN J S， et al. CD33-targeted lipid nanoparticles （aCD33LNs） for therapeutic delivery of GTI-2040 to acute myelogenous leukemia［J］. Mol Pharmaceut， 2015， 12（6）： 2010-2018.
62	BAEUMER N， SCHELLER A， WITTMANN L， et al. Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia［J］. J Hematol Oncol， 2022， 15（1）： 171.
63	YONG S B， CHUNG J Y， KIM S S， et al. CD64-targeted HO-1 RNA interference enhances chemosensitivity in orthotopic model of acute myeloid leukemia and patient-derived bone marrow cells［J］. Biomaterials， 2020， 230： 119651.
64	YONG S B， KIM J， CHUNG J Y， et al. Heme oxygenase 1-targeted hybrid nanoparticle for chemo- and immuno-combination therapy in acute myelogenous leukemia［J］. Adv Sci， 2020， 7（13）： 2000487.
65	JIN L Q， HOPE K J， ZHAI Q L， et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells［J］. Nat Med， 2006， 12（10）： 1167-1174.
66	PELED A， KLEIN S， BEIDER K， et al. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies［J］. Cytokine， 2018， 109： 11-16.
67	RIVERA D， ALVARADO Y， GARCIA-MANERO G， et al. Clinical characteristics and outcomes of patients diagnosed with acute myeloid leukemia with expression of CD71［J］. Blood， 2021， 138： 151023.
68	VAN DE DONK N W C J， RICHARDSON P G， MALAVASI F. CD38 antibodies in multiple myeloma： back to the future［J］. Blood， 2018， 131（1）： 13-29.
69	KISHIMOTO H， HOSHINO S， OHORI M， et al. Molecular mechanism of human CD38 gene expression by retinoic acid-identification of retinoic acid response element in the first intron［J］. J Biol Chem， 1998， 273（25）： 15429-15434.
70	SPERR W R， FLORIAN S， HAUSWIRTH A W， et al. CD33 as a target of therapy in acute myeloid leukemia： current status and future perspectives［J］. Leuk Lymphoma， 2005， 46（8）： 1115-1120.
71	SADEGHI M， FATHI M， NAVASHENAQ J G， et al. The prognostic and therapeutic potential of HO-1 in leukemia and MDS［J］. Cell Commun Signal， 2023， 21（1）： 57.
72	WU H， GAO Y， MA J， et al. Cytarabine delivered by CD44 and bone targeting redox-sensitive liposomes for treatment of acute myelogenous leukemia［J］. Regen Biomater， 2022， 9： rbac058.
73	SUN S， ZOU H， LI L， et al. CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape［J］. Int J Pharm， 2019， 568： 118518.
74	WANG X Q， HUANG R H， WU W， et al. Amplifying STING activation by bioinspired nanomedicine for targeted chemo-and immunotherapy of acute myeloid leukemia［J］. Acta Biomater， 2023， 157： 381-394.
75	LI Q， SU R， BAO X， et al. Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy［J］. Acta Biomater， 2022， 144： 109-120.
76	CHEN M， QIAO Y Y， CAO J， et al. Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia［J］. J Nanobiotechnol， 2022， 20（1）： 273.
77	KONG F， HE H L， BAI H Y， et al. A biomimetic nanocomposite with enzyme-like activities and CXCR4 antagonism efficiently enhances the therapeutic efficacy of acute myeloid leukemia［J］. Bioact Mater， 2022， 18： 526-538.

Nanoparticles	Target	Ligand	Drug	Mouse model	Ref.
Polymeric prodrug	CD44	HA	6-Mercaptopurine	Subcutaneous OCI/AML-2	［47］
HA-EGCG micelle	CD44	HA	Sorafenib	Orthotopic AML-PDX	［48］
Liposome	CD44	HA	Curcumin	Orthotopic KG-1	［49］
Lipid-polymer hybrid Nanoparticle	CD44	HA	DOX & gallic acid	Subcutaneous HL-60/ADR	［50］
Polymersome	CD44	A6	Vincristine sulfate	Orthotopic MV4-11-Luc	［51］
T22-GFP-H6	CXCR4	T22 peptide	Cytarabine	Orthotopic THP-1-Luc	［52］
T22-GFP-H6	CXCR4	T22 peptide	MMAE	Orthotopic THP-1-Luc	［53］
T22-mRTA-H6	CXCR4	T22 peptide	Ricin	Orthotopic THP-1-Luc	［54］
T22-DITOX-H6	CXCR4	T22 peptide	Diphtheria toxin	Orthotopic THP-1-Luc	［55］
Polymersome	CD71	Transferrin	Volasertib	Orthotopic MV4-11-Luc	［56］
Ferritin	CD71	Ferritin	Arsenic trioxide	Orthotopic HL-60-Luc	［57］
Ferritin heavy chain （HFn）	CD71	HFn	Cytarabine	Orthotopic HL-60-Luc	［58］
Polymersome	CD38	Daratumumab	Vincristine sulfate	Orthotopic Molm-13-Luc & MV4-11 Orthotopic Molm-13-Luc & MV4-11	［59］
Polymersome	CD38	Daratumumab	Volasertib		［60］
Liposome	CD33	Anti-CD33 scFv	GTI-2040	Subcutaneous Kasumi-1	［61］
Protamine vesicles	CD33	Anti-CD33 antibody	DNMT3A/FLT3-siRNA	Subcutaneous OCI/AML2， KG1 & MV4-11	［62］
Fusion protein	CD64	anti-CD64 scFv	HO-1 siRNA	Orthotopic U937	［63］
Lipid-polymer hybrid nanoparticle	CD64	anti-CD64 scFv	SnMP	Orthotopic U937	［64］

Nanoparticles	Target	Ligand	Drug	Mouse model	Ref.
Polymeric prodrug	CD44	HA	6-Mercaptopurine	Subcutaneous OCI/AML-2	［47］
HA-EGCG micelle	CD44	HA	Sorafenib	Orthotopic AML-PDX	［48］
Liposome	CD44	HA	Curcumin	Orthotopic KG-1	［49］
Lipid-polymer hybrid Nanoparticle	CD44	HA	DOX & gallic acid	Subcutaneous HL-60/ADR	［50］
Polymersome	CD44	A6	Vincristine sulfate	Orthotopic MV4-11-Luc	［51］
T22-GFP-H6	CXCR4	T22 peptide	Cytarabine	Orthotopic THP-1-Luc	［52］
T22-GFP-H6	CXCR4	T22 peptide	MMAE	Orthotopic THP-1-Luc	［53］
T22-mRTA-H6	CXCR4	T22 peptide	Ricin	Orthotopic THP-1-Luc	［54］
T22-DITOX-H6	CXCR4	T22 peptide	Diphtheria toxin	Orthotopic THP-1-Luc	［55］
Polymersome	CD71	Transferrin	Volasertib	Orthotopic MV4-11-Luc	［56］
Ferritin	CD71	Ferritin	Arsenic trioxide	Orthotopic HL-60-Luc	［57］
Ferritin heavy chain （HFn）	CD71	HFn	Cytarabine	Orthotopic HL-60-Luc	［58］
Polymersome	CD38	Daratumumab	Vincristine sulfate	Orthotopic Molm-13-Luc & MV4-11 Orthotopic Molm-13-Luc & MV4-11	［59］
Polymersome	CD38	Daratumumab	Volasertib		［60］
Liposome	CD33	Anti-CD33 scFv	GTI-2040	Subcutaneous Kasumi-1	［61］
Protamine vesicles	CD33	Anti-CD33 antibody	DNMT3A/FLT3-siRNA	Subcutaneous OCI/AML2， KG1 & MV4-11	［62］
Fusion protein	CD64	anti-CD64 scFv	HO-1 siRNA	Orthotopic U937	［63］
Lipid-polymer hybrid nanoparticle	CD64	anti-CD64 scFv	SnMP	Orthotopic U937	［64］

[1]	Yue ZHANG, Rui LIANG, Can-Nan ZHAO, Chun-Mei LI. Construction of Graphene Oxide-DNA Nanoprobe for Adenosine 5-Triphosphate Detection and Drug Delivery [J]. Chinese Journal of Applied Chemistry, 2024, 41(1): 118-127.
[2]	Xiao-Ying LIU, Fang-Min CHEN, Hui-Juan ZHANG, Hai-Jun YU. Advancement of Cyclodextrin-Based Host-Guest Drug Delivery System for Antitumor Therapy [J]. Chinese Journal of Applied Chemistry, 2023, 40(7): 964-975.
[3]	Xin-Tao XIE, Sang-Ni JIANG, Xi-Fei YU. Selective Binding pH Responsive Liposomes with Phenylboronic Acid for Drug Delivery [J]. Chinese Journal of Applied Chemistry, 2023, 40(6): 860-870.
[4]	Yuan-Hua ZHANG, Sheng-Ran LI, Xi-Fei YU. Fluoride-Functionalized Choline Phosphate Liposomes for Oral Insulin Administration [J]. Chinese Journal of Applied Chemistry, 2023, 40(5): 730-742.
[5]	Hui DU, Chen-Yang YAO, Hao PENG, Bo JIANG, Shun-Xiang LI, Jun-Lie YAO, Fang ZHENG, Fang YANG, Ai-Guo WU. Applications of Transition Metal⁃doped Iron⁃based Nanoparticles in Biomedicine [J]. Chinese Journal of Applied Chemistry, 2022, 39(3): 391-406.
[6]	CHENG Cui-Lin, MA Jia-Pei, WANG Wei-Chen, WANG Bo-Yang, WANG Zhen-Yu. Application of Electrospinning Technology of Natural Products in Biomedicine [J]. Chinese Journal of Applied Chemistry, 2021, 38(6): 605-614.
[7]	XIA Ying, XIA Jing, CUI Hongyan, QIAN Ming, ZHANG Liuwei, CHEN Qixian, WANG Jingyun. Homologous Cell Membrane Coated Smart Drug-Release Nanoparticles for Targeted Hepatocellular Carcinoma Therapy [J]. Chinese Journal of Applied Chemistry, 2020, 37(1): 69-79.
[8]	FAN Ye, HAN Yichen, XIA Yongmei, BO Chunling, WANG Shuyu, FANG Yun. Investigation on Self-assembly of Nanocontainers by Vesiculation of Conjugated Linoleic Acid and Sodium Alginate and Their Drug Delivery Behavior [J]. Chinese Journal of Applied Chemistry, 2018, 35(12): 1478-1484.
[9]	HUANG Qiongwei,ZHAO Li,SONG Zhiming,FENG Xiangru,DING Jianxun. Phenylboronic Acid-Based Glucose-Sensitive Polymer Nanocarriers Used as Drug Delivery Systems [J]. Chinese Journal of Applied Chemistry, 2017, 34(7): 733-743.
[10]	JIAN Yong, DING Ru, LIU Shu, LIU Zhongying, SONG Fengrui, LIU Zhiqiang. Comparison of the Pharmacokinetics Difference Between Acanthopanax Leaf Flavonoids Liposome and Acanthopanax Leaf Drop Pills [J]. Chinese Journal of Applied Chemistry, 2017, 34(1): 118-122.
[11]	ZHANG Yi, WU Lingbo, HU Qian, CHEN Baoxin, Wu Boyang, XUE Wei . Functionally Modified Hyperbranched Polyglycerols for Drug Delivery [J]. Chinese Journal of Applied Chemistry, 2015, 32(4): 367-378.
[12]	WU Cheng-Yao1, XIE Jian-Gang1,2, QUAN Jing1, ZHU Li-Min1, BAO Jin-Yue3, ZHOU Hong-Qiang3. Preparation and Sustained-release of Ketoprofen Polymeric Prodrug with Glucose Pendant [J]. Chinese Journal of Applied Chemistry, 2010, 27(12): 1386-1391.

Research Progress on the Application of Nanomedicines in the Treatment of Acute Myeloid Leukemia

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 77

Related Articles 12

Recommended Articles

Metrics

Comments